# Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

> **NCT07702032** · PHASE3 · RECRUITING · sponsor: **Genmab** · enrollment: 960 (estimated)

## Conditions studied

- Left-sided Colorectal Cancer

## Interventions

- **DRUG:** Petosemtamab
- **DRUG:** Cetuximab
- **DRUG:** FOLFIRI
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT07702032
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-11
- **Primary completion:** 2029-07
- **Final completion:** 2031-09
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702032, "Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*